The miR-34 family and its clinical significance in ovarian cancer.
carcinogenesis
miR-34
ovarian cancer
p53
survival
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
02
2019
accepted:
20
11
2019
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
13
2
2020
Statut:
epublish
Résumé
The tumor suppressor miR-34 family is transcriptionally induced by p53. Clinical significance of the various miR-34 family members has not been studied in ovarian cancer. In 228 ovarian cancers and in 19 non-neoplastic fallopian tube samples we analysed miR-34 a/b/c expression in relation to clinicopathological characteristics and clinical outcome. We found significantly lower levels of miR-34 a/b/c in ovarian cancers as compared to control-tissues (
Identifiants
pubmed: 32047551
doi: 10.7150/jca.33831
pii: jcav11p1446
pmc: PMC6995379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1446-1456Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Carcinogenesis. 2009 Nov;30(11):1903-9
pubmed: 19736307
Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34
pubmed: 27898521
Br J Cancer. 2012 Jan 3;106(1):189-98
pubmed: 22108517
Cancer Res. 2014 Dec 15;74(24):7573-82
pubmed: 25368020
Cell Cycle. 2007 May 2;6(9):1006-10
pubmed: 17457049
Nat Rev Cancer. 2009 Oct;9(10):701-13
pubmed: 19693097
Int J Oncol. 2011 May;38(5):1189-95
pubmed: 21399872
Curr Biol. 2007 Aug 7;17(15):1298-307
pubmed: 17656095
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Genes Dev. 2012 Jun 15;26(12):1268-86
pubmed: 22713868
Gynecol Oncol. 2009 Aug;114(2):253-9
pubmed: 19446316
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancer Res. 2010 Jun 1;70(11):4613-23
pubmed: 20460525
Cell Death Dis. 2017 Oct 12;8(10):e3100
pubmed: 29022903
Cell Death Differ. 2010 Feb;17(2):193-9
pubmed: 19461653
Cancer Res. 2007 Dec 1;67(23):11099-101
pubmed: 18056431
Lancet Oncol. 2016 Aug;17(8):1137-1146
pubmed: 27402147
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Mol Cell Biol. 2014 Jun;6(3):214-30
pubmed: 24815299
Virchows Arch. 2011 Mar;458(3):313-22
pubmed: 21225432
BMC Res Notes. 2012 Mar 27;5:164
pubmed: 22452920
Cell Adh Migr. 2012 Jul-Aug;6(4):374-84
pubmed: 22796939
Cancer Res. 2007 Sep 15;67(18):8433-8
pubmed: 17823410
Cancer Cell. 2007 Nov;12(5):414-8
pubmed: 17996645
Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39
pubmed: 29232473
Ann Oncol. 2016 Apr;27 Suppl 1:i45-i49
pubmed: 27141071
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Mol Cell. 2007 Jun 8;26(5):745-52
pubmed: 17540599
Oncogene. 2011 Sep 22;30(38):4038-49
pubmed: 21516127
Mol Cell. 2007 Jun 8;26(5):731-43
pubmed: 17540598
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
Ann Oncol. 2012 Jul;23(7):1795-802
pubmed: 22228447
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
pubmed: 18458333
J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50
pubmed: 23781004
Am J Surg Pathol. 2009 Aug;33(8):1220-4
pubmed: 19461510
J Exp Clin Cancer Res. 2016 Sep 05;35(1):132
pubmed: 27596137
Oncotarget. 2014 Jan 30;5(2):462-72
pubmed: 24497324
Cell Cycle. 2011 Dec 15;10(24):4256-71
pubmed: 22134354
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
pubmed: 22193408
Clin Cancer Res. 2010 Feb 15;16(4):1119-28
pubmed: 20145172
Nature. 2007 Jun 28;447(7148):1130-4
pubmed: 17554337
PLoS One. 2009 Oct 02;4(10):e7314
pubmed: 19798417
PLoS Genet. 2012;8(7):e1002797
pubmed: 22844244
Obstet Gynecol. 2002 Aug;100(2):281-7
pubmed: 12151151